Hennion & Walsh Asset Management, Inc. Amylyx Pharmaceuticals, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.59 Billion
- Q3 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 47,898 shares of AMLX stock, worth $732,360. This represents 0.03% of its overall portfolio holdings.
Number of Shares
47,898
Previous 56,831
15.72%
Holding current value
$732,360
Previous $364,000
78.57%
% of portfolio
0.03%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding AMLX
# of Institutions
145Shares Held
75.8MCall Options Held
212KPut Options Held
40.6K-
Adage Capital Partners Gp, L.L.C. Boston, MA8.8MShares$135 Million0.1% of portfolio
-
Perceptive Advisors LLC New York, NY7.9MShares$121 Million2.22% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$90.9 Million7.77% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.54MShares$69.4 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$68.8 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $895M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...